Trial Profile
Open-Label, Cooperative, Randomized, Multicenter Phase III Study on the Use of Cisplatin Resistant Genotype (ERCC1 Over-Expression) in Tumor RNA to Customize Chemotherapy in Stage IV-IIIB (Malignant Pleural Effusion) Non-Small-Cell Lung Cancer Patients
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Cisplatin; Gemcitabine
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 24 Jun 2008 Patient inclusion/exclusion criteria and actual patient numbers added as reported by ClinicalTrials.gov.
- 13 Aug 2007 Status changed from in progress to completed.
- 21 Oct 2005 New trial record.